Surat, August 14, 2024: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended June 30, 2024.
Consolidated Financial Highlights for quarter ended June 30, 2024:
§ Total revenue for Q1FY25 was at ₹2,603 million as compared to ₹3,988 million in Q1FY24.
§ EBITDA (incl. other income) was at ₹592 million in Q1FY25 as compared to ₹1,138 million in Q1FY24, this would translate into 23% EBITDA margin in this quarter.
§ Profit After Tax was at ₹122 million in Q1FY25 as compared to ₹523 million in Q1FY24.
Speaking on the performance, Mr. Anand Desai, Managing Director, Anupam Rasayan commented, “Agro chemical industry is facing significant headwinds since last one year. We anticipate this trend to persist until the end of H1FY25, after which we expect demand to strengthen. This coupled with our polymer and pharma segment ramping up, we expect our revenue growth to come back from H2FY25.
Our consolidated operating revenue for the quarter stood at ₹254 crores with a YoY de-growth of 34%. The EBITDA margin was at 23% in Q1FY25. Compression in the EBITDA margins was largely due to the lower volumes offtake for the quarter. We expect this number to normalize as the volume picks up in the later half of the year.
We expect all our plants to be commercialized this year. With the new capacity, ramp-up of the recently launched Fluorinated molecules and LOIs & Contracts we had signed, we expect robust growth over the medium term.”